Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients

Fig. 2

Anti-SARS-CoV-2 antibodies maintenance over time. IgG(S-RBD) were quantified after two (n = 88, Panel A) or three (n = 45, Panel B) vaccine doses (at a mean follow-up of 59 ± 17 and 103 ± 25 days following the first vaccine dose, respectively) and compared with IgG(S-RBD) quantified at 6 months (at a mean follow-up of 184 ± 15 days following the first vaccine dose). Panel C shows Spearman correlation between IgG(S-RBD) quantified (1) at the peak value after the second or third vaccine dose and (2) at 6 months after the first vaccine dose. The calculated correlation coefficient was 0.582 (95% CI 0.457–0.684, p = 2 × 10E−13). Panel D shows receiver operating characteristic (ROC) curve analysis for predicting IgG(S-RBD) titer above 1000 AU/mL at 6 months after vaccination. Initial IgG(S-RBD) levels were quantified after the second (n = 88) or, in case, the third (n = 45) vaccine dose. The area under curve for late humoral protection was 0.883 (95% CI 0.823–0.944)

Back to article page